

Hanoi, April 1, 2025

DỰ THẢO

REPORT OF THE AUDIT COMMITTEE
VIETNAM VETERINARY PRODUCTS JOINT STOCK COMPANY I

(Presented to the Annual General Meeting of Shareholders 2025)

Dear Shareholders and Distinguished Delegates.

- Based on the Charter and operational regulations of the Vietnam Veterinary Products Joint Stock Company I
- Implementing the functions and tasks assigned, the Audit Committee of the Joint Stock Company of Central Veterinary Medicine I has conducted control over the Company's operations in 2024, now wishes to report to the General Meeting of Shareholders with the main contents as follows:

Part I: Summary of the activities of the Audit Committee.

- The Audit Committee has operated according to the Enterprise Law and the Company's Charter, on behalf of the Shareholders to control the production and business activities and management of the Company.

The Audit Committee has assigned specific tasks to each member in each field suitable to their professional qualifications. The members regularly exchange information, work via email, phone, and direct communication, ensuring smooth and timely communication, in line with the Company's operational and production activities

In 2024, the Audit Committee organized 02 meetings regarding the activities of the Audit Committee in the first 6 months of the year and summarized the activities of 2024. The meetings were fully attended by the participating members

The members of the Audit Committee have made efforts to fully participate in all Board of Directors meetings and have also accessed all production and business activities of the Company.

Part II: Remuneration and other benefits of the Audit Committee

The remuneration of the Board of Directors and the Audit Committee in 2024 has been disbursed according to Resolution No. 19-2024/NQ AGMS of the Company's General Meeting of Shareholders approved on 04/05/2024 and is detailed in the financial report for 2024, specifically:

Unit of measurement: dong

No.	DESCRIPTION	AMOUNT OF COMPENSATION RECEIVED ACCORDING TO NQ No. 19 2024 /NQ AGM
1	Nguyen Anh Tuan	36.000.000
2	Nguyen Viet Hoang	24.000.000
3	Phan Quoc Duy	16.000.000
4	Bui Huong Lien	8.000.000
	Total	84.000.000

Part III: Results of monitoring the operational and financial situation of the Company

1. Results of production and business activities in 2024 of the Company:

At the end of the 2024 financial year, the Board of Directors directed the Executive Board to prepare the financial report, and the financial report was audited by UHY Audit and Consulting Company Limited.

The Supervisory Board agreed with the assessments of the operations and finances in the Company's financial report and the auditing unit with the main indicators as follows:

Results of production and business activities in 2024

Unit: Thousand dong

Financial indicators	Year 2023	Year 2024	% increase/decrease
Net revenue from sales of goods and rendering of services	94.339.484.657	109.113.684.605	15,66%
Operating profit	2.588.981.277	4.274.591.547	65,11%
Net profit before tax	4.268.778.453	5.093.646.511	19,32%

Financial indicators	Year 2023	Year 2024	% increase/decrease
Net profit after tax	3.381.284.688	3.777.670.212	11,72%
Current liabilities	41.548.941.702	42.042.724.462	1,19%
Profit distribution	0%	0%	

(Source: Consolidated audited financial statements for 2024 of Central Vietnam Veterinary Products Joint Stock Company I)

- According to the financial report for 2024 ending on 31/12/2024, the results achieved are as follows:

+ Net revenue from sales and services reached: 109,113,684,605 dong, only achieving 99.19% of the annual plan.

+ Profit after tax reached: 3,777,670,212 dong, only achieving 75.55% of the annual plan.

+ Short-term liabilities decreased by 41,548,941,702 dong, an increase of 1.19% compared to the same period last year.

UBKT evaluates the financial statements for 2024 to be prepared and presented honestly, in accordance with Vietnamese accounting standards and current regulations.

In 2024, no fraud or potential fraud risks were detected in the financial statements.

2. Transactions with Subsidiaries and Related Parties of the Company

Transactions between Central Veterinary Medicine Joint Stock Company I and its subsidiaries and related parties are conducted in accordance with regulations. The Audit Committee did not detect any abnormalities in these transactions.

Part IV: Results of Monitoring the Board of Directors and Executive Board

- In 2024, the Board of Directors of the Company held direct meetings. All meetings were conducted in accordance with the procedures specified in the Charter of Central Veterinary Medicine Joint Stock Company I and the Enterprise Law. Through the actual situation and the audited financial statements of the Company, the Audit Committee also did not find anything unusual in the operation and management process of the Company.

- The Executive Board has made significant efforts in managing the Company's production and business activities according to the direction set by the Board of Directors. However, the accumulated losses over many consecutive years remain a significant financial pressure for the Company. The Board of Directors and the Executive Board have also actively sought solutions to enhance and consolidate the market, regain the Company's market share

by implementing an increase in the number of new products, new product lines, as well as improving product quality to bring to the market, and closely connecting with the entire customer system.

- The Board of Directors sets the plan target for 2025 with net revenue of 124,200,000,000 VND and after-tax profit of 5,100,000,000 VND, which is appropriate for the actual situation.

Part V: Results of Evaluating the Internal Control System and Risk Management of the Company, Assessing the Independence and Objectivity of the Independent Audit

The implementation of internal control is well executed, ensuring that business units follow the correct procedures. The Company has issued and strictly implemented internal control and risk management processes in accordance with legal regulations. The selected auditing company (UHY Auditing and Consulting Company Limited) ensures reliability, honesty, compliance with audit deadlines, adherence to professional regulations, and maintains independence and objectivity when providing audit opinions. The Audit Committee did not detect any issues regarding conflicts of interest, independence, or objectivity of the auditors, the audit team, or the auditing company when conducting audit work.

Part VI: Plan Targets for 2025 and Implementation Solutions of the Audit Committee

I. Current Situation at the Company

Through the process of reviewing the activities of the entire Company, the Board of Directors and the Audit Committee have agreed to require the branch to complete the tax inspection for all years that have not been inspected to date and prepare all procedures to close the tax code due to the branch's ineffective operation and lack of feasible direction to resolve existing issues.

At the Ho Chi Minh City branch, the tax debt situation has just been resolved, therefore the tax code closure at the Ho Chi Minh City branch has not yet been implemented

II. Plan targets for 2025:

The year 2025 is a year significantly affected by fluctuations in the economy. Based on the revenue and profit results achieved in 2024, the Board of Directors has established the plan targets for 2024 with a net revenue of 124,200,000,000 VND and a post-tax profit of 5,100,000,000 VND, which is appropriate for the actual situation. However, the Board of Directors needs to clearly recognize the existing difficulties of the Company to have appropriate policies and timely directives for the Executive Board to organize implementation to achieve the goals.

III. Recommendations and Solutions for implementation in 2025 for the Board of Directors

1. Recommendations:

Based on the actual business situation of 2024, our Audit Committee makes the following recommendations:

The Company needs to continue reviewing and evaluating personnel work, continue restructuring to enhance the operational efficiency of the units.

The Company needs to have a clear direction in its business strategy, consolidate and stabilize what the company already has, serving as a basis and premise for new development, improving and enhancing capacity based on development trends in the specific industry.

2. Solutions:

In 2025, the Company's financial situation has somewhat resolved the difficulties. For the Company to develop, the Audit Committee recommends implementing the following basic solutions:

a. For the office at 88 Truong Chinh:

The revenue obtained in the year mainly comes from leasing premises, in addition, the number of staff operating the entire workload of the unit at the office is only 3 people. Therefore, the Board of Directors and the Executive Board need to have a plan to strengthen the workforce. The Company also needs to have a compensation policy that is commensurate with the general standards of each position and each common task across the entire Company system, ensuring alignment with the contributions of each employee so that workers can fully utilize their capabilities to bring benefits to the Company as well as to the employees.

Implement the development of veterinary medicine business at the Company office to create a source to offset payable costs.

b. For Central Veterinary Company Limited 1

**** With the overall activities of the entire company:***

Although the economy faces many difficulties, the Board of Directors and the Executive Board have united to propose directions for the production and business activities of the entire company, but the results achieved are still limited. The Board of Directors and the Executive Board have been and are making great efforts to implement Resolution No. 19/2024/NQĐHĐCĐ of the General Meeting of Shareholders. Therefore, in 2025, the

company needs to strive to improve product quality and increase more products in the market to gain market share.

regaining market share, increasing sales, and promoting the effectiveness of investment capital. Urgently rectify and complete the accumulated losses to bring benefits to the shareholders of the company.

*** With the production and business activities of Veterinary Medicine and Aquaculture:**

The diseases related to livestock are always complicated, therefore the Company needs to focus resources on researching new products suitable for each period and organizing production to timely supply the market. The Company needs to have appropriate sales care policies so that customers can cooperate and accompany the Company in business activities, ensuring that both parties are assured of their entitled benefits.

In addition, it is necessary to select members who have enough dedication, capability, and enthusiasm in business activities, while the company also needs to have a compensation policy that is commensurate with the contributions of each employee so that workers can wholeheartedly promote their abilities, bringing benefits to both the company and the employees.

Dear Congress, the Audit Committee recognizes that to date, the difficulties of the Company have been somewhat alleviated. If there is effort from the Board of Directors, the Executive Board, the Audit Committee believes that in 2025, the Company will overcome some difficulties, achieve the set goals, and meet the expectations of the shareholders.

Above is the activity report of the Audit Committee of Central Veterinary Medicine Joint Stock Company I in the past period, respectfully submitted to the General Meeting of Shareholders for approval.

The Audit Committee sincerely thanks the esteemed Shareholders

Wishing the congress success./.

ON BEHALF OF THE AUDIT COMMITTEE

Chairman of the Audit Committee



NGUYEN VIET HOANG.